Congenital Melanocytic Nevus Management

Classification and Risk Assessment

Congenital melanocytic nevi (CMN) are present in approximately 1-3.6% of newborns and carry a lifetime melanoma risk of 0.7-1.7% 1, 3
CMN are classified into three main subtypes: "Classic" - brown/black macules, papules, patches or plaques with possible nodules, Blue - gray-blue patches or plaques with possible nodules, and Nevus spilus - brown patch with darker overlying macules/papules 1, 4

Initial evaluation of CMN should include visual inspection (aided by dermoscopic evaluation when available), palpation, regional lymph node examination, and serial photographs to monitor changes over time 5, 2
MRI screening is recommended for patients with multiple medium CMN, ≥10 "satellite" lesions, or giant CMN, but not for solitary small, medium, and large CMN unless neurological signs/symptoms are present 2, 6

The American Academy of Pediatrics recommends immediate dermatology referral for large, giant, or multiple CMN of any size, and referral for small/medium CMN with concerning features (color variation, nodules, symptoms) 1, 2
Skin care recommendations include bathing with water or nonsoap cleanser 2-3 times weekly followed by bland emollient, and photoprotection following AAP UV radiation protection guidelines (clothing, hats) 1, 7, 6
Parents should monitor nevi visually and with palpation between visits, and report concerning changes: rapid growth, bleeding, pain, nodules, or ulceration 5, 6

Histopathologic examination of concerning changes should be performed by a dermatopathologist with expertise in pediatric pigmented lesions 2, 8
Patients with confirmed neurocutaneous melanosis (NCM) should be referred to pediatric neurology 2, 8
CMN may undergo normal changes including spontaneous lightening, changes in pigmentation pattern, and textural changes, which should be recognized to avoid unnecessary concern 1, 8